미국의 동맥 외과용 지혈 실란트 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 최종 용도별, 용도별, 질환 적응별 및 부문별 예측(2026-2033년)

U.S. Hemostatic Sealants in Arterial Surgery Market Summary

The U.S. hemostatic sealants in arterial surgery market size was estimated at USD 95.5 million in 2025 and is projected to reach USD 114.6 million by 2033, growing at a CAGR of 2.3% from 2026 to 2033. Market growth is primarily driven by the increasing burden of peripheral artery disease (PAD), aortic aneurysms, and other vascular disorders requiring surgical intervention.

According to the CDC, nearly 8.5 million Americans are affected by PAD, with the disease being particularly prevalent among the aging population and patients with diabetes, hypertension, obesity, and smoking-related cardiovascular conditions. The growing volume of arterial bypass procedures, aneurysm repairs, carotid endarterectomies, and other complex vascular surgeries is increasing the demand for advanced hemostatic sealants that can reduce intraoperative bleeding, improve surgical efficiency, and lower the risk of postoperative complications.

In addition, the rising adoption of minimally invasive and endovascular procedures, along with continuous technological advancements in bioresorbable and synthetic sealant products, is further supporting market expansion. Government initiatives and healthcare organizations are also emphasizing improved cardiovascular care and surgical outcomes, encouraging hospitals and surgical centers to adopt advanced bleeding management solutions. Together, these factors are contributing to the increasing utilization of hemostatic sealants in arterial surgery across the U.S.

The U.S. is the most dominant and most procedure-intensive national market for hemostatic sealants in arterial surgery in North America. Its combination of the world's largest absolute vascular surgery caseload, a rapidly aging cardiovascular patient population, a well-resourced hospital infrastructure, and a favorable FDA regulatory environment makes it the single most important geography for hemostatic sealant manufacturers operating in the arterial surgery segment. The four key disease indications, namely, aortic aneurysms, peripheral artery disease, carotid artery disease, and other acute conditions, including aortic dissection and traumatic arterial injury, each generate a distinct and well-defined CPT-coded procedural demand base that directly drives hemostatic sealant utilization.

U.S. Hemostatic Sealants in Arterial Surgery Market Report Segmentation

This report forecasts revenue growth at the country level and analyzes the latest industry trends in each sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. hemostatic sealants in arterial surgery market report based on product, application, disease indication, and end use:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Fibrin-based Sealants
• Synthetic/Polymer-based Sealants
• Combination Hemostats & Sealants
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Arterial Surgery with Graft Replacement (Artificial Vessel Replacement)
  • 35556, 35566
  • 35656, 35661, 35666
  • 35081, 35082, 35091, 35092, 35102, 35103
  • 33858, 33859, 33863, 33864, 33871, 33875, 33877
• Arterial Repair/Reconstruction without Graft
  • 35301
  • 35371
  • 35206
  • 35286
  • 35226, 35256
• Disease Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Aortic Aneurysms
  • Peripheral Artery Disease
  • Carotid Artery Disease
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Public Hospitals
  • Private Hospitals

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. Disease Indication
  • 1.2.4. End-use
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Application outlook
  • 2.2.3. Disease Indication outlook
  • 2.2.4. End-use outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Hemostatic Sealants in Arterial Surgery Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing clinical evidence supporting sealant effectiveness in vascular surgery
    • 3.2.1.2. Advancements in synthetic and bioactive hemostatic technologies
    • 3.2.1.3. Favorable insurance coverage and reimbursement
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of advanced hemostatic sealants
    • 3.2.2.2. Risk of product-related complications
  • 3.2.3. Market Opportunity Analysis
    • 3.2.3.1. Increasing adoption of minimally invasive arterial surgeries
    • 3.2.3.2. Development of next-
• 3.3. U.S. Hemostatic Sealants in Arterial Surgery Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. U.S. Hemostatic Sealants in Arterial Surgery Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Hemostatic Sealants in Arterial Surgery Market: Product Movement Analysis
• 4.3. U.S. Hemostatic Sealants in Arterial Surgery Market by Product Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
• 4.5. Fibrin-based Sealants
  • 4.5.1. Fibrin-based Sealants Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.2. Synthetic/Polymer-based Sealants
    • 4.5.2.1. Synthetic/Polymer-based Sealants Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.3. Combination Hemostats & Sealants
    • 4.5.3.1. Combination Hemostats & Sealants Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Hemostatic Sealants in Arterial Surgery Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Hemostatic Sealants in Arterial Surgery Market: Application Movement Analysis
• 5.3. U.S. Hemostatic Sealants in Arterial Surgery Market by Application Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
• 5.5. Arterial Surgery with Graft Replacement (Artificial Vessel Replacement)
  • 5.5.1. Arterial Surgery with Graft Replacement (Artificial Vessel Replacement) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.1.1. 35556, 35566
      • 5.5.1.1.1. 35556, 35566 Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.1.2. 35656, 35661, 35666
      • 5.5.1.2.1. 35656, 35661, 35666 Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.1.3. 35081, 35082, 35091, 35092, 35102, 35103
      • 5.5.1.3.1. 35081, 35082, 35091, 35092, 35102, 35103 Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.1.4. 33858, 33859, 33863, 33864, 33871, 33875, 33877
      • 5.5.1.4.1. 33858, 33859, 33863, 33864, 33871, 33875, 33877 Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Arterial Repair/Reconstruction without Graft
  • 5.6.1. Arterial Repair/Reconstruction without Graft Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.6.1.1. 35301
      • 5.6.1.1.1. 35301 Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.6.1.2. 35371
      • 5.6.1.2.1. 35371 Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.6.1.3. 35206
      • 5.6.1.3.1. 35206 Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.6.1.4. 35286
      • 5.6.1.4.1. 35286 Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.6.1.5. 35226, 35256
      • 5.6.1.5.1. 35226, 35256 Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Hemostatic Sealants in Arterial Surgery Market: Disease Indication Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. Hemostatic Sealants in Arterial Surgery Market: Disease Indication Movement Analysis
• 6.3. U.S. Hemostatic Sealants in Arterial Surgery Market by Disease Indication Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
• 6.5. Aortic Aneurysms
  • 6.5.1. Aortic Aneurysms Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Peripheral Artery Disease
  • 6.6.1. Peripheral Artery Disease Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Carotid Artery Disease
  • 6.7.1. Carotid Artery Disease Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Others
  • 6.8.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Hemostatic Sealants in Arterial Surgery Market: End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. U.S. Hemostatic Sealants in Arterial Surgery Market: End Use Movement Analysis
• 7.3. U.S. Hemostatic Sealants in Arterial Surgery Market by End Use Outlook (USD Million)
• 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
• 7.5. Public Hospitals
  • 7.5.1. Public Hospitals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Private Hospitals
  • 7.6.1. Private Hospitals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Key Company Profiles
  • 8.2.1. Ethicon
    • 8.2.1.1. Company overview
    • 8.2.1.2. Financial performance
    • 8.2.1.3. Product benchmarking
    • 8.2.1.4. Strategic initiatives
  • 8.2.2. Baxter International
    • 8.2.2.1. Company overview
    • 8.2.2.2. Financial performance
    • 8.2.2.3. Product benchmarking
    • 8.2.2.4. Strategic initiatives
  • 8.2.3. Corza Medical
    • 8.2.3.1. Company overview
    • 8.2.3.2. Financial performance
    • 8.2.3.3. Product benchmarking
    • 8.2.3.4. Strategic initiatives
  • 8.2.4. Integra LifeSciences Corporation
    • 8.2.4.1. Company overview
    • 8.2.4.2. Financial performance
    • 8.2.4.3. Product benchmarking
    • 8.2.4.4. Strategic initiatives
  • 8.2.5. Artivion
    • 8.2.5.1. Company overview
    • 8.2.5.2. Financial performance
    • 8.2.5.3. Product benchmarking
    • 8.2.5.4. Strategic initiatives
  • 8.2.6. Becton, Dickinson and Company (BD)
    • 8.2.6.1. Company overview
    • 8.2.6.2. Financial performance
    • 8.2.6.3. Product benchmarking
    • 8.2.6.4. Strategic initiatives
  • 8.2.7. Teleflex
    • 8.2.7.1. Company overview
    • 8.2.7.2. Financial performance
    • 8.2.7.3. Product benchmarking
    • 8.2.7.4. Strategic initiatives